Amy­lyx to vol­un­tar­i­ly with­draw ALS drug Re­lyvrio af­ter Phase 3 fail, will lay off around 70%

Amy­lyx an­nounced Thurs­day morn­ing that it will pull its ALS drug Re­lyvrio from the US and Cana­di­an mar­kets.

The de­ci­sion comes as Amy­lyx will al­so lay off around 70% of its work­force in or­der to ex­tend its cash run­way to 2026, it said in a press re­lease. Re­lyvrio will not be avail­able for new pa­tients as of to­day, but pa­tients who are cur­rent­ly tak­ing the ther­a­py can con­tin­ue to do so for free.

“While this is a dif­fi­cult mo­ment for the ALS com­mu­ni­ty, we reached this path for­ward in part­ner­ship with the stake­hold­ers who will be im­pact­ed and in line with our stead­fast com­mit­ment to peo­ple liv­ing with ALS and oth­er neu­rode­gen­er­a­tive dis­eases,” co-CEOs Justin Klee and Joshua Co­hen said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER